Cancer Products

The cancer market is growing at a faster rate than any other pharmaceutical market due to an ageing population in developed countries and more effective therapies being introduced. It is a specialist area with a small number of highly influential opinion leaders defining treatment guidelines. As such it is an ideal market for Protherics to develop and sell niche cancer products to capture the full commercial value of these products.

We have four products in development which aim to improve outcomes in the treatment of cancer. Our lead programme is Voraxaze™ (glucarpidase), an intervention treatment when methotrexate blood levels remain dangerously elevated following high dose therapy for the treatment of cancer.

For more information on our cancer products please click on the product name.

Products

Voraxaze™ is currently available on a named patient basis. Please see below. 

Research and Development

TECHNOLOGY USE STATUS PARTNER MARKET
Voraxaze™
Recombinant enzyme Treatment of patients experiencing or at risk of methotrexate toxicity due to delayed elimination

Rolling BLA filing in H2 2008

Available on named patient basis in EU and RoW. Supplied by AAIPharma under a Treatment Protocol in US

Various local distribution outside US Global market potential of US$25-50 million for intervention use

>US$100 million including planned use
OncoGel™
Injectable sustained-released paclitaxel formulation Oesophageal cancer

Primary brain cancer

Phase 2b study ongoing in oesophageal cancer   Phase 1/2 study in primary brain cancer

 Diatos outside North America, Mexico and Korea US market potential of >US$250 million
Prolarix™
Prodrug based selective chemotherapy Primary liver cancer Cancer Research UK (CRUK) phase 1 study in UK reported. Phase 2 study planned for mid 2008 Partner sought for Asia Global market potential of ~US$1 billion
Acadra™
Nucleoside analogue B-cell chronic lymphocytic leukaemia (B-CLL) Clinical proof-of-concept phase 1/2 study initiated and preliminary results expected in 2009 Codevelopment with Advanced In Vitro Cell Technologies (Advancell). Protherics has exclusive global commercialization rights >US$200 million globally

 * Based on Protherics estimates